CHMP rec­om­mends re­ject­ing Amy­lyx ALS drug, pit­ting EMA against FDA and Health Cana­da

The Eu­ro­pean Med­i­cines Agency rec­om­mend­ed that Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug be re­ject­ed with­in the EU.

The drug, known as Re­lyvrio in the US and Al­bri­oza in Cana­da and the EU, did not “con­vinc­ing­ly” show that it could slow the wors­en­ing of ALS in a clin­i­cal tri­al, the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) said Fri­day. As a re­sult, reg­u­la­tors could not say for cer­tain that the ben­e­fits out­weigh the risks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER